Community-acquired pneumonia in HIV-infected children: A global perspective

Current Opinion in Pulmonary Medicine

Volumn 16, Issue 3, 2010, Pages 208-216

  Gray, D M ^a   Zar, H J ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Child; HIV; Morbidity; Mortality; Pneumonia

Indexed keywords

AMOXICILLIN; AMPICILLIN; ATOVAQUONE; BETA LACTAM; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN; CHLORAMPHENICOL; CLINDAMYCIN; CLOXACILLIN; COTRIMOXAZOLE; DAPSONE; ETHAMBUTOL; FOLINIC ACID; GANCICLOVIR; GENTAMICIN; ISONIAZID; OSELTAMIVIR; PENICILLIN G; PENTAMIDINE; PREDNISONE; PRIMAQUINE; PYRAZINAMIDE; RETINOL; RIFAMPICIN; STREPTOMYCIN; TRIMETHOPRIM; TRIMETREXATE GLUCURONATE; UNINDEXED DRUG; VANCOMYCIN;

BACTERIAL PNEUMONIA; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DOSE RESPONSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLUENZA; LUNG TUBERCULOSIS; MEASLES; MORTALITY; PATHOGENESIS; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PROGNOSIS; PROPHYLAXIS; REVIEW; RISK ASSESSMENT; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIA;

AGE DISTRIBUTION; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; COMMUNITY-ACQUIRED INFECTIONS; DISEASE OUTBREAKS; FEMALE; HUMANS; INCIDENCE; INFECTION CONTROL; MALE; PNEUMONIA, BACTERIAL; PNEUMONIA, PNEUMOCOCCAL; PRIMARY PREVENTION; PROGNOSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; WORLD HEALTH;

EID: 77951051967     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e3283387984     Document Type: Review

References (96)

1. WHO. World Health Statistics. In World Health Organisation www.who.int/ whosis/whostat/EN-WHS09-Full.pdf; 2009 Accessed 28 November 2009.
2. UNAIDS 2009 AIDS epidemic update. http://data.unaids.org/pub/Report/ 2009/2009-epidemic-update-en.pdf. [Accessed 28 November 2009]
3. Rudan I, Boschi-Pinto C, Biloglav Z, et al. Epidemiology and etiology of childhood pneumonia. Bull World Health Organ 2008; 86:408-416.
4. Gona P, Van Dyke RB, Williams PL, et al. Incidence of opportunistic and other infections in HIV-infected children in the HAART era. J Am Med Assoc 2006; 296:292-300.
5. Chiappini E, Galli L, Tovo PA, et al. Changing patterns of clinical events in perinatally HIV-1-infected children during the era of HAART. AIDS 2007; 21:1607-1615.
6. Nesheim SR, Kapogiannis BG, Soe MM, et al. Trends in opportunistic infections in the pre and posthighly active antiretroviral therapy eras among HIV-infected children in the Perinatal AIDS Collaborative Transmission Study, 1986-20004. Pediatrics 2007; 120:100-109.
7. Towards universal access. Scaling up priority HIV/AIDS interventions in the health sector. Progress report 2009. In. Edited by World Health Organisation UNICEF, UNAIDS; 2009.
8. Nachman S, Gona P, Dankner W, et al. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis. Pediatrics 2005; 115:e488-e494.
9. Jaspan HB, Huang LC, Cotton MF, et al. Bacterial disease and antimicrobial susceptibility patterns in HIV-infected, hospitalized children: a retrospective cohort study. PLoS One 2008; 3:e3260.
10. Mubiana-Mbewe M, Bolton-Moore C, Banda Y, et al. Causes of morbidity among HIV-infected children on antiretroviral therapy in primary care facilities in Lusaka, Zambia. Trop Med Int Health 2009; 14:1190-1198.
11. Mulenga V, Ford D, Walker AS, et al. Effect of cotrimoxazole on causes of death, hospital admissions and antibiotic use in HIV-infected children. AIDS 2007; 21:77-84.
12. McNally LM, Jeena PM, Gajee K, et al. Effect of age, polymicrobial disease, and maternal HIV status on treatment response and cause of severe pneumonia in South African children: a prospective descriptive study. Lancet 2007; 369:1440-1451.
13. Mussi-Pinhata MM, Freimanis L, Yamamoto AY, et al. Infectious disease morbidity among young HIV-1-exposed but uninfected infants in Latin American and Caribbean countries: the National Institute of Child Health and Human Development International Site Development Initiative Perinatal Study. Pediatrics 2007; 119:e694-e704.
14. Slogrove AL, Cotton MF, Esser MM. Severe infections in HIV-exposed uninfected infants: clinical evidence of immunodeficiency. J Trop Pediatr 2009; Jul 14 [Epub ahead of print].
15. Kuhn L, Kasonde P, Sinkala M, et al. Does severity of HIV disease in HIVinfected mothers affect mortality and morbidity among their uninfected infants? Clin Infect Dis 2005; 41:1654-1661.
16. Mermin J, Lule J, Ekwaru JP, et al. Cotrimoxazole prophylaxis by HIV-infected persons in Uganda reduces morbidity and mortality among HIV-uninfected family members. AIDS 2005; 19:1035-1042.
17. de Moraes-Pinto MI, Almeida AC, Kenj G, et al. Placental transfer and maternally acquired neonatal IgG immunity in human immunodeficiency virus infection. J Infect Dis 1996; 173:1077-1084.
18. Zar HJ, Hanslo D, Tannenbaum E, et al. Aetiology and outcome of pneumonia in human immunodeficiency virus-infected children hospitalized in South Africa. Acta Paediatr 2001; 90:119-125.
19. Madhi SA, Petersen K, Madhi A, et al. Increased disease burden and antibiotic resistance of bacteria causing severe community-acquired lower respiratory tract infections in human immunodeficiency virus type 1-infected children. Clin Infect Dis 2000; 31:170-176.
20. O'Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009; 374:893-902.
21. Zar HJ, Madhi SA. Pneumococcal conjugate vaccine: a health priority. S Afr Med J 2008; 98:463-467.
22. Bliss SJ, O'Brien KL, Janoff EN, et al. The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease. Lancet Infect Dis 2008; 8:67-80.
23. Calder D, Qazi S. Evidence behind the WHO guidelines: hospital care for children: what is the aetiology of pneumonia in HIV-infected children in developing countries? J Trop Pediatr 2009; 55:219-224.
24. Zar HJ, Apolles P, Argent A, et al. The etiology and outcome of pneumonia in human immunodeficiency virus-infected children admitted to intensive care in a developing country. Pediatr Crit Care Med 2001; 2:108-112.
25. Cotton MF, Wasserman E, Smit J, et al. High incidence of antimicrobial resistant organisms including extended spectrum beta-lactamase producing Enterobacteriaceae and methicillin-resistant Staphylococcus aureus in nasopharyngeal and blood isolates of HIV-infected children from Cape Town, South Africa. BMC Infect Dis 2008; 8:40.
26. Schaaf HS, Marais BJ, Whitelaw A, et al. Culture-confirmed childhood tuberculosis in Cape Town, South Africa: a review of 596 cases. BMC Infect Dis 2007; 7:140.
27. Hesseling AC, Cotton MF, Jennings T, et al. High incidence of tuberculosis among HIV-infected infants: evidence from a South African population-based study highlights the need for improved tuberculosis control strategies. Clin Infect Dis 2009; 48:108-114.
28. Lawn SD, Bekker LG, Middelkoop K, et al. Impact of HIV infection on the epidemiology of tuberculosis in a peri-urban community in South Africa: the need for age-specific interventions. Clin Infect Dis 2006; 42:1040-1047.
29. Madhi SA, Schoub B, Simmank K, et al. Increased burden of respiratory viral associated severe lower respiratory tract infections in children infected with human immunodeficiency virus type-1. J Pediatr 2000; 137:78-84.
30. Madhi SA, Ludewick H, Kuwanda L, et al. Seasonality, incidence, and repeat human metapneumovirus lower respiratory tract infections in an area with a high prevalence of human immunodeficiency virus type-1 infection. Pediatr Infect Dis J 2007; 26:693-699.
31. Dankner WM, Lindsey JC, Levin MJ. Correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy. Pediatr Infect Dis J 2001; 20:40-48.
32. Chintu C, Mudenda V, Lucas S, et al. Lung diseases at necropsy in African children dying from respiratory illnesses: a descriptive necropsy study. Lancet 2002; 360:985-990.
33. Bakeera-Kitaka S, Musoke P, Downing R, Tumwine JK. Pneumocystis carinii in children with severe pneumonia at Mulago Hospital, Uganda. Ann Trop Paediatr 2004; 24:227-235.
34. Morrow BM, Hsaio NY, Zampoli M, et al. Pneumocystis pneumonia in South- African HIV-infected and uninfected infants in the era of highly active antiretroviral therapy. Pediatr Infect Dis J 2010; Jan 12 [Epub ahead of print].
35. Sazawal S, Black RE. Effect of pneumonia case management on mortality in neonates, infants, and preschool children: a meta-analysis of communitybased trials. Lancet Infect Dis 2003; 3:547-556.
36. Enarson PM, Gie R, Enarson DA, Mwansambo C. Development and implementation of a national programme for the management of severe and very severe pneumonia in children in Malawi. PLoS Med 2009; 6:e1000137.
37. Marsh DR, Gilroy KE, Van de Weerdt R, et al. Community case management of pneumonia: at a tipping point? Bull World Health Organ 2008; 86:381-389.
38. Kallander K, Nsungwa-Sabiiti J, Balyeku A, et al. Home and community management of acute respiratory infections in children in eight Ugandan districts. Ann Trop Paediatr 2005; 25:283-291.
39. WHO. Management of children with pneumonia and HIV in low-resource settings: report on a consultative meeting, Harare, Zimbabwe, 30-31 January, 2003. WHO; 2004.
40. Duke T, Wandi F, Jonathan M, et al. Improved oxygen systems for childhood pneumonia: a multihospital effectiveness study in Papua New Guinea. Lancet 2008; 372:1328-1333.
41. Roth DE, Caulfield LE, Ezzati M, Black RE. Acute lower respiratory infections in childhood: opportunities for reducing the global burden through nutritional interventions. Bull World Health Organ 2008; 86:356-364.
42. Asghar R, Banajeh S, Egas J, et al. Chloramphenicol versus ampicillin plus gentamicin for community acquired very severe pneumonia among children aged 2-59 months in low resource settings: multicentre randomised controlled trial (SPEAR study). Br Med J 2008; 336:80-84.
43. Cardoso MR, Nascimento-Carvalho CM, Ferrero F, et al. Penicillin-resistant pneumococcus and risk of treatment failure in pneumonia. Arch Dis Child 2008; 93:221-225.
44. Clinical efficacy of 3 days versus 5 days of oral amoxicillin for treatment of childhood pneumonia: a multicentre double-blind trial. Lancet 2002; 360: 835-841.
45. Three day versus five day treatment with amoxicillin for nonsevere pneumonia in young children. A multicentre randomised controlled trial. Br Med J 2004; 328:791-794.
46. Zar HJ, Alvarez-Martinez MJ, Harrison A, Meshnick SR. Prevalence of dihydropteroate synthase mutants in HIV-infected South African children with Pneumocystis jiroveci pneumonia. Clin Infect Dis 2004; 39:1047-1051.
47. Mofenson LM, Brady MT, Danner SP, et al. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep 2009; 58 (RR-11):1-166.
48. Briel M, Bucher HC, Boscacci R, Furrer H. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV-infection. Cochrane Database Syst Rev 2006; 3:CD006150.
49. Sleasman JW, Hemenway C, Klein AS, Barrett DJ. Corticosteroids improve survival of children with AIDS and Pneumocystis carinii pneumonia. Am J Dis Child 1993; 147:30-34.
50. Bye MR, Cairns-Bazarian AM, Ewig JM. Markedly reduced mortality associated with corticosteroid therapy of Pneumocystis carinii pneumonia in children with acquired immunodeficiency syndrome. Arch Pediatr Adolesc Med 1994; 148:638-641.
51. McLaughlin GE, Virdee SS, Schleien CL, et al. Effect of corticosteroids on survival of children with acquired immunodeficiency syndrome and Pneumocystis carinii-related respiratory failure. J Pediatr 1995; 126 (5 Pt 1):821-824.
52. American Academy of Pediatrics. Pickering LK, editor. Red Book: 2009 report of the Committee on Infectious Diseases, 28th ed.: Elk Grove Village, IL: American Academy of Pediatrics; 2009.
53. Kovacs A, Schluchter M, Easley K, et al. Cytomegalovirus infection and HIV-1 disease progression in infants born to HIV-1-infected women. Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection Study Group. N Engl J Med 1999; 341:77-84.
54. Kitchen BJ, Engler HD, Gill VJ, et al. Cytomegalovirus infection in children with human immunodeficiency virus infection. Pediatr Infect Dis J 1997; 16:358-363.
55. Beadsworth MB, Cohen D, Ratcliffe L, et al. Autopsies in HIV: still identifying missed diagnoses. Int J STD AIDS 2009; 20:84-86.
56. Martinson NA, Karstaedt A, Venter WD, et al. Causes of death in hospitalized adults with a premortem diagnosis of tuberculosis: an autopsy study. AIDS 2007; 21:2043-2050.
57. Ansari NA, Kombe AH, Kenyon TA, et al. Pathology and causes of death in a series of human immunodeficiency virus-positive and -negative pediatric referral hospital admissions in Botswana. Pediatr Infect Dis J 2003; 22:43-47.
58. Ren Y, Nuttall JJ, Eley BS, et al. Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr 2009; 50:439-443.
59. Ren Y, Nuttall JJ, Egbers C, et al. Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr 2008; 47:566-569.
60. Fu LY, Ruthazer R, Wilson I, et al. Brief hospitalization and pulse oximetry for predicting amoxicillin treatment failure in children with severe pneumonia. Pediatrics 2006; 118:e1822-e1830.
61. Mamtani M, Patel A, Hibberd PL, et al. A clinical tool to predict failed response to therapy in children with severe pneumonia. Pediatr Pulmonol 2009; 44:379-386.
62. Tiewsoh K, Lodha R, Pandey RM, et al. Factors determining the outcome of children hospitalized with severe pneumonia. BMC Pediatr 2009; 9:15.
63. Patel A, Mamtani M, Hibberd PL, et al. Value of chest radiography in predicting treatment response in children aged 3-59 months with severe pneumonia. Int J Tuberc Lung Dis 2008; 12:1320-1326.
64. Subhi R, Adamson M, Campbell H, et al. The prevalence of hypoxaemia among ill children in developing countries: a systematic review. Lancet Infect Dis 2009; 9:219-227.
65. Lodha R, Bhadauria PS, Kuttikat AV, et al. Can clinical symptoms or signs accurately predict hypoxemia in children with acute lower respiratory tract infections? Indian Pediatr 2004; 41:129-135.
66. Ayieko P, English M. In children aged 2-59 months with pneumonia, which clinical signs best predict hypoxaemia? J Trop Pediatr 2006; 52:307-310.
67. Laman M, Ripa P, Vince J, Tefuarani N. Can clinical signs predict hypoxaemia in Papua New Guinean children with moderate and severe pneumonia? Ann Trop Paediatr 2005; 25:23-27.
68. Shet A, Mehta S, Rajagopalan N, et al. Anemia and growth failure among HIVinfected children in India: a retrospective analysis. BMC Pediatr 2009; 9:37.
69. Gakidou E, Oza S, Vidal Fuertes C, et al. Improving child survival through environmental and nutritional interventions: the importance of targeting interventions toward the poor. J Am Med Assoc 2007; 298:1876-1887.
70. Walker AS, Mulenga V, Sinyinza F, et al. Determinants of survival without antiretroviral therapy after infancy in HIV-1-infected Zambian children in the CHAP Trial. J Acquir Immune Defic Syndr 2006; 42:637-645.
71. Black RE, Allen LH, Bhutta ZA, et al. Maternal and child undernutrition: global and regional exposures and health consequences. Lancet 2008; 371:243-260.
72. Brooks WA, Santosham M, Naheed A, et al. Effect of weekly zinc supplements on incidence of pneumonia and diarrhoea in children younger than 2 years in an urban, low-income population in Bangladesh: randomised controlled trial. Lancet 2005; 366:999-1004.
73. Niessen LW, ten Hove A, Hilderink H, et al. Comparative impact assessment of child pneumonia interventions. Bull World Health Organ 2009; 87:472-480.
74. Bobat R, Coovadia H, Stephen C, et al. Safety and efficacy of zinc supplementation for children with HIV-1 infection in South Africa: a randomised double-blind placebo-controlled trial. Lancet 2005; 366:1862-1867.
75. HusseyGD, Klein M. A randomized, controlled trial of vitamin A in children with severe measles. N Engl J Med 1990; 323:160-164.
76. Kirkwood BR, Gove S, Rogers S, et al. Potential interventions for the prevention of childhood pneumonia in developing countries: a systematic review. Bull World Health Organ 1995; 73:793-798.
77. Cutts FT, Zaman SM, Enwere G, et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005; 365:1139-1146. (Pubitemid 40417563)
78. Madhi SA, Kuwanda L, Cutland C, Klugman KP. The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children. Clin Infect Dis 2005; 40:1511-1518.
79. Madhi SA, Kuwanda L, Cutland C, et al. Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children. Pediatr Infect Dis J 2005; 24:410-416.
80. Madhi SA, Adrian P, Kuwanda L, et al. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and noninfected children in the absence of a booster dose of vaccine. Vaccine 2007; 25:2451-2457.
81. Madhi SA, Petersen K, Khoosal M, et al. Reduced effectiveness of Haemophilus influenzae type b conjugate vaccine in children with a high prevalence of human immunodeficiency virus type 1 infection. Pediatr Infect Dis J 2002; 21:315-321.
82. WHO. Influenza vaccination. Wkly Epidemiol Rec (WER) 2005; 80:279-287.
83. Atashili J, Kalilani L, Adimora AA. Efficacy and clinical effectiveness of influenza vaccines in HIV-infected individuals: a meta-analysis. BMC Infect Dis 2006; 6:138.
84. Hesseling AC, Johnson LF, Jaspan H, et al. Disseminated bacille Calmette- Guerin disease in HIV-infected South African infants. Bull World Health Organ 2009; 87:505-511.
85. Hesseling AC, Rabie H, Marais BJ, et al. Bacille Calmette-Guerin vaccineinduced disease in HIV-infected and HIV-uninfected children. Clin Infect Dis 2006; 42:548-558.
86. Mansoor N, Scriba TJ, de Kock M, et al. HIV-1 infection in infants severely impairs the immune response induced by Bacille Calmette-Guerin vaccine. J Infect Dis 2009; 199:982-990.
87. Braitstein P, Nyandiko W, Vreeman R, et al. The clinical burden of tuberculosis among human immunodeficiency virus-infected children in western Kenya and the impact of combination antiretroviral treatment. Pediatr Infect Dis J 2009; 28:626-632.
88. Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008; 359:2233-2244.
89. Goetghebuer T, Haelterman E, Le Chenadec J, et al. Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants. AIDS 2009; 23:597-604.
90. WHO. Report of the WHO Technical Reference Group, Paediatric HIV/ART Care Guideline Group Meeting In Geneva; 2008.
91. Chintu C, Bhat GJ, Walker AS, et al. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a doubleblind randomised placebo-controlled trial. Lancet 2004; 364:1865-1871.
92. Guidelines for cotrimoxazole prophylaxis for HIV-related infection among children, adolescents and adults in resource-limited settings. Recommendations for a public health approach. WHO 2006. http://www.who.int/hiv/pub/ guidelines/ctxguidelines.pdf. [Accessed July 2009]
93. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2004:CD000171.
94. Golub JE, Pronyk P, Mohapi L, et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS 2009; 23:631-636.
95. Zar HJ, Cotton MF, Strauss S, et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. Br Med J 2007; 334:136.
96. Gray DM, Zar H, Cotton M. Impact of tuberculosis preventive therapy on tuberculosis and mortality in HIV-infected children. Cochrane Database Syst Rev 2009:CD006418.